The U.S. Food and Drug Administration (FDA) authorized revised fact sheets for healthcare providers to include additional information on susceptibility of SARS-CoV-2 variants to each of the monoclonal antibody (mAb) therapies that are available through an Emergency Use Authorization (EUA) for the treatment of COVID-19. FDA is providing this information to equip healthcare providers with the most current data so they can make informed decisions and provide appropriate care to patients with COVID-19. Healthcare providers should review the fact sheets for details regarding specific variants and potential resistance that may make the authorized mAb therapies less effective.
The revised fact sheets are for:

Read More